Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on November 29, 2004

Arteriosclerosis, Thrombosis, and Vascular Biology. 2004
Published online before print November 29, 2004, doi: 10.1161/01.ATV.0000151647.14923.ec
A more recent version of this article appeared on February 1, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/2/287    most recent
01.ATV.0000151647.14923.ecv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Undas, A.
Right arrow Articles by Mann, K. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Undas, A.
Right arrow Articles by Mann, K. G.

Submitted on October 4, 2004
Accepted on November 12, 2004

Statins and Blood Coagulation

Anetta Undas ; Kathleen E. Brummel-Ziedins ; and Kenneth G. Mann *

From the Department of Medicine (A.U.), Jagiellonian University School of Medicine, Krakow, Poland; and the Department of Biochemistry (K.E.B.Z., K.G.M.), University of Vermont, Burlington.

* To whom correspondence should be addressed. E-mail: kenneth.mann{at}uvm.edu.

Abstract--The 3hydroxy3methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors (statins) have been shown to exhibit several vascular protective effects, including antithrombotic properties, that are not related to changes in lipid profile. There is growing evidence that treatment with statins can lead to a significant downregulation of the blood coagulation cascade, most probably as a result of decreased tissue factor expression, which leads to reduced thrombin generation. Accordingly, statin use has been associated with impairment of several coagulant reactions catalyzed by this enzyme. Moreover, evidence indicates that statins, via increased thrombomodulin expression on endothelial cells, may enhance the activity of the protein C anticoagulant pathway. Most of the antithrombotic effects of statins are attributed to the inhibition of isoprenylation of signaling proteins. These novel properties of statins, suggesting that these drugs might act as mild anticoagulants, may explain, at least in part, the therapeutic benefits observed in a wide spectrum of patients with varying cholesterol levels, including subjects with acute coronary events.


Key words: statins • blood coagulation • thrombin • protein C




This article has been cited by other articles:


Home page
CirculationHome page
D. J. Schneider and B. E. Sobel
Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs
Circulation, July 17, 2007; 116(3): 305 - 315.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
S. C. Fagan, H. F. Elewa, and D. J. Rychly
Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice
Journal of Pharmacy Practice, April 1, 2007; 20(2): 117 - 122.
[Abstract] [PDF]


Home page
Canadian J. AnesthesiaHome page
N. N. Boushra and M. Muntazar
Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives: [Le role des statines dans la reduction du risque cardiaque perioperatoire : perspectives physiologiques et cliniques].
Can J Anesth, November 1, 2006; 53(11): 1126 - 1147.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. R. Bach
Tissue Factor Encryption
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 456 - 461.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Pignatelli, V. Sanguigni, B. Buchetti, L. Lenti, F. Violi, A. Undas, and K. G. Mann
Early Anticoagulant Effect of Atorvastatin
Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): e145 - e146.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Undas, M. Celinska-Lowenhoff, K. E. Brummel-Ziedins, J. Brozek, A. Szczeklik, and K. G. Mann
Simvastatin Given for 3 Days Can Inhibit Thrombin Generation and Activation of Factor V and Enhance Factor Va Inactivation in Hypercholesterolemic Patients
Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1524 - 1525.
[Full Text] [PDF]